Next Article in Journal
Increased Alpha-Fetoprotein Receptor in the Serum of Patients with Early-Stage Breast Cancer
Previous Article in Journal
Major Histocompatibility Complex Class I and Tumour Immuno-Evasion: How to Fool T Cells and Natural Killer Cells at One Time
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 19
Issue 1
10.3747/co.19.949
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions

by
I. Karam
1 and
B. Melosky
2,*
1
Department of Radiation Oncology, BC Cancer Agency, Vancouver, BC, Canada
2
Department of Medical Oncology, BC Cancer Agency, Vancouver, BC, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2012, 19(1), 42-46; https://doi.org/10.3747/co.19.949
Submission received: 2 November 2011 / Revised: 4 December 2011 / Accepted: 8 January 2012 / Published: 1 February 2012

Abstract

Erlotinib—an oral tyrosine kinase inhibitor (tki) of the epidermal growth factor receptor (egfr)—has commonly been used as a therapeutic option in metastatic non-small-cell lung cancer (nsclc) patients in the second- or third-line treatment setting. A mutation in the EGFR gene (EGFR M+) confers an increased response to this class of drugs. In the first-line setting, use of tkis is restricted to patients having a mutation. The importance of this biomarker has been questioned in subsequent treatment lines. Here, we report a case showing a positive response to erlotinib treatment in the second-line setting. The patient, an elderly male smoker with stage iv nsclc, had a tumour that was EGFR mutation-negative (wild-type EGFR). Based on this clinical case, we discuss the controversy concerning the need for, and impact of, testing for EGFR mutation after first-line treatment.
Keywords: non-small-cell lung cancer; gefitinib; erlotinib; EGFR mutation non-small-cell lung cancer; gefitinib; erlotinib; EGFR mutation

Share and Cite

MDPI and ACS Style

Karam, I.; Melosky, B. Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions. Curr. Oncol. 2012, 19, 42-46. https://doi.org/10.3747/co.19.949

AMA Style

Karam I, Melosky B. Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions. Current Oncology. 2012; 19(1):42-46. https://doi.org/10.3747/co.19.949

Chicago/Turabian Style

Karam, I., and B. Melosky. 2012. "Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions" Current Oncology 19, no. 1: 42-46. https://doi.org/10.3747/co.19.949

APA Style

Karam, I., & Melosky, B. (2012). Response to Second-Line Erlotinib in an EGFR Mutation-Negative Patient with Non-Small-Cell Lung Cancer: Make No Assumptions. Current Oncology, 19(1), 42-46. https://doi.org/10.3747/co.19.949

Article Metrics

Back to TopTop